Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S (SG:T14) has released an update.
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has passed resolutions at their latest board meeting to approve the sale of a 13% stake in Tianjin TSKF Pharmaceutical Co., Ltd. to Haleon China Co., Ltd. for RMB 1.75 billion, as part of a larger disposal involving its controlling shareholder. Post-transaction, the company will retain a 12% stake, with the controlling shareholder exiting the joint venture. The board confirmed the accuracy and fairness of the information provided, with interested directors abstaining from the vote.
For further insights into SG:T14 stock, check out TipRanks’ Stock Analysis page.
